Trials / Completed
CompletedNCT02376595
Pharmacokinetic and Pharmacodynamic of Rocuronium
Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Pontificia Universidad Catolica de Chile · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rocuronium Bromide | Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus. |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2013-11-01
- Completion
- 2015-01-01
- First posted
- 2015-03-03
- Last updated
- 2015-03-03
Source: ClinicalTrials.gov record NCT02376595. Inclusion in this directory is not an endorsement.